ANTIGEN-SPECIFIC ANTIBODIES APPLICATION ON TUBERCULOSIS

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). Mtb is an airborne transmitted pathogen, and the immune responses, especially the mucosal immune response, play fundamental roles for the host to defend the primary and the containment of Mtb infection. It remains a significant health threat to mankind and is undoubtedly the most successful disease caused by a single infectious agent ever. TB killed ∼1.5 million individuals in 2018 alone, and a total of around 1,000,000,000 people over the last 200 years. The Bacillus Calmette‑Guerin immunization is the as it was authorized immunization against TB, but its protective impact does not amplify to controlling the improvement of irresistible pulmonary disease in grown‑ups. To develop improved vaccines and a new method for controlling TB, an important element is the discovery of markers to measure the effectors’ mechanisms of the protective immune response against M. tuberculosis. Humoral responses are conspicuous during active TB illness and have indeed been hypothesized to contribute to immunopathology. In any case, there's proof to recommend that particular antibodies may restrain the dispersal of MTB, and possibly play a part in the avoidance of disease through mucosal resistance. Further, antibodies are now understood to confer protection against a run of intracellular pathogens by modulating immunity via means of Fc‑receptor mediated phagocytosis. The objective of the present study will be to review antigen-specific antibodies application in Tuberculosis and their potential utility as biomarkers and their functional contribution to Mtb control.